Evelo Biosciences, a microbiome company launched by Flagship, shuts down; Living in cancer limbo

Taking stock of the drug industry, from the lab to the medicine chest

November 22, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Evelo Biosciences, a microbiome company launched by Flagship, shuts down The biotech, which was based in Cambridge, Mass., launched in 2015 and was one of the first companies in the microbiome field. By Allison DeAngelis Opinion: Listen: Living in cancer limbo A philosopher who has cancer and his wife, a social medicine expert, discuss diagnostic tests, Stoicism, cancer language, and more. By Torie Bosch STAT+ | Health tech startups warn that overregulating AI could hamper innovation Startups racing to bring the power of AI into health care are urging Washington to consider the risk of overregulation hampering innovation. By Mohana Ravindranath APU GOMES/AFP via Getty Images Opinion: Physician and Rep. Raul Ruiz: The infectious disease doctor shortage threatens future pandemic preparedness In 2017, 80% of U.S. counties didn't have a single infectious disease specialist. The shortage will only get worse in the coming decade. By Raul Ruiz

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser